Jacqueline Rosenthal, MD

Acute lesions are only one part of MS biology. Compartmentalized inflammation behind the blood-brain barrier suggests a network problem that targeting a single cell type cannot fully solve.

A decade of diagnostic, biologic, and therapeutic change has shifted MS from fixed phenotypes toward a spectrum, and distinguishing disease activity, impact, and progression clarifies what current treatment still leaves unaddressed.